bi 1823911
Solid Tumors, KRAS Mutation
Boehringer IngelheimPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Solid Tumors, KRAS Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MIDAZOLAM Boehringer Ingelheim | Phase 1 | CC |
bi 1701963 Boehringer Ingelheim | Phase 1 | C |
bi 3011441 Boehringer Ingelheim | Phase 1 | NR |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →